Levophacetoperane
Tools
Actions
General
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
(Redirected from Phacetoperane)
Stimulant drug
Pharmaceutical compound
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H19NO2 |
Molar mass | 233.311 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Levophacetoperane (Lidépran, Phacétoperane) is a psychostimulant developed by Rhône-Poulenc in the 1950s.[2] The drug has been used as an antidepressant and anorectic.[3][4] It is the reverse ester of methylphenidate. Phacetoperane and levophacetoperane have been used as wakefulness-promoting agents in the treatment of narcolepsy.[5]
See also
[edit]References
[edit]- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ US 2928835, Marie JN, Michel JR, "New esters", published 15 March 1960, assigned to Rhône-Poulenc
- ^ Delbeke FT, Debackere M (March 1975). "Isolation and detection of methylphenidate, phacetoperane and some other sympatomimetic central nervous stimulants with special reference to doping. I. Gas chromatographic detection procedure with electron capture detection for some secondary amines". Journal of Chromatography. 106 (2): 412–7. doi:10.1016/S0021-9673(00)93853-6. PMID 239015.
- ^ US 20150038533, Konofal E, Figadere B, "Phacetoperane for the treatment of attention-deficit hyperactivity disorder", published 5 February 2015, assigned to Assistance Publique – Hôpitaux de Paris
- ^ Konofal E (August 2024). "From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacol Biochem Behav. 241: 173804. doi:10.1016/j.pbb.2024.173804. PMID 38852786.
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
DATTooltip Dopamine transporter (DRIsTooltip Dopamine reuptake inhibitors) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NETTooltip Norepinephrine transporter (NRIsTooltip Norepinephrine reuptake inhibitors) |
| ||||||||||||||
SERTTooltip Serotonin transporter (SRIsTooltip Serotonin reuptake inhibitors) |
| ||||||||||||||
VMATsTooltip Vesicular monoamine transporters | |||||||||||||||
Others |
| ||||||||||||||
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- CS1 Brazilian Portuguese-language sources (pt-br)
- Articles with short description
- Short description is different from Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes which contain changes to watched fields
- All stub articles